Table 1.

Clinical endpoints

Primary endpoints
% change in atheroma volume (PAV) in thoracic aorta
LV mass regression
Secondary endpoints
Central aortic SBP
24‐hour mean SBP
Insulin resistance (HOMA‐IR) at 6 weeks
Tertiary measures
Evaluate miRNAs involved in regulating MR expression and differentially regulated miRNAs as predictors of disease progression and response
Monocyte inflammatory activation in spironolactone vs placebo groups at 6 weeks

Abbreviations: HOMA‐IR, homeostatic model assessment of insulin resistance; LV, left ventricular; miRNA, microRNA; MR, mineralocorticoid receptor; SBP, systolic blood pressure.